Evidence map›Paper›PMID 36433728›Full record

ArticleEuropean journal of haematology2023

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma.

Maurus Locher, Emina Jukic, Verena Vogi, Markus A Keller, Teresa Kröll, Simon Schwendinger, Klaus Oberhuber, Irmgard Verdorfer, Beatrix E Mühlegger, Martina Witsch-Baumgartner and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 2 countries.

Maurus LocherInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-9299-3454
Emina JukicInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0001-6909-7005
Verena VogiInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Markus A KellerInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-8654-9920
Teresa KröllInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Simon SchwendingerInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-7542-222X
Klaus OberhuberInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Irmgard VerdorferInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Beatrix E MühleggerInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Martina Witsch-BaumgartnerInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-9379-5345
David NachbaurInternal Medicine V (Hematology & Oncology), Medical University of Innsbruck, Innsbruck, Austria.
Wolfgang WillenbacherInternal Medicine V (Hematology & Oncology), Medical University of Innsbruck, Innsbruck, Austria.
Eberhard GunsiliusInternal Medicine V (Hematology & Oncology), Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0003-1327-2921
Dominik WolfInternal Medicine V (Hematology & Oncology), Medical University of Innsbruck, Innsbruck, Austria.
Johannes ZschockeInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Normann SteinerInternal Medicine V (Hematology & Oncology), Medical University of Innsbruck, Innsbruck, Austria.
Innsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-term disease control in multiple myeloma (MM) is typically an unmet medical need, and most patients experience multiple relapses. Fluorescence in situ hybridization (FISH) is the standard technique to detect chromosomal abnormalities (CAs), which are important to estimate the prognosis of MM and the allocation of risk adapted therapies. In advanced stages, the importance of CAs needs further investigation. From 148 MM patients, two or more paired samples, at least one of which was collected at relapse, were analyzed by FISH. Using targeted next-generation sequencing, we molecularly investigated samples harboring relapse-associated CAs. Sixty-one percent of the patients showed a change in the cytogenetic profile during the disease course, including 10% who acquired high-risk cytogenetics. Amp(1q) (≥4 copies of 1q21), driven by an additional increase in copy number in patients who already had 3 copies of 1q21, was the most common acquired CA with 16% affected patients. Tetraploidy, found in 10% of the samples collected at the last time-point, was unstable over the course of the disease and was associated with TP53 lesions. Our results indicate that cytogenetic progression is common in relapsed patients. The relatively high frequency of amp(1q) suggests an active role for this CA in disease progression.

Indexed as

Adenine PhosphoribosyltransferaseMultiple MyelomaTetraploidyChromosome AberrationsHumansIn Situ Hybridization, FluorescenceNeoplasm Recurrence, LocalPrognosisTumor Suppressor Protein p53Adenine PhosphoribosyltransferaseTP53 protein, humanTumor Suppressor Protein p53chromosome aberrationsmultiple myelomarecurrencetetraploidy

Identifiers

PMID36433728
PMCPMC10107198
OpenAlexW4310296180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.